Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. - Sharma MR; Powderly J; Kuboki Y; Strickler JH; Perets R; Cohen JE; Raimbourg J; Nakajima TE; Yamamoto N; Cruz-Correa M; O'Neil B; Ghiringhelli F; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026)